Nivolumab for Recurrent/Metastatic Carcinosarcoma

NCT05224999 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Recurrent/Metastatic Carcinosarcoma

Interventions

DRUG: nivolumab

Sponsor

Yonsei University